Reference trademark issue [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2018-07-24 11:05 (1957 d 06:59 ago) – Posting: # 19087
Views: 2,374

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.

Regards'
Kakarla

Complete thread:

UA Flag
Activity
 Admin contact
22,811 posts in 4,783 threads, 1,632 registered users;
19 visitors (0 registered, 19 guests [including 5 identified bots]).
Forum time: 17:04 CET (Europe/Vienna)

Inspiration is constantly in the air.
It’s up to us to develop the sensitivity
to pick up on it.    Herbie Hancock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5